Cellosaurus logo
expasy logo

Cellosaurus UKF-NB-3rCDDP1000 (CVCL_M478)

[Text version]
Cell line name UKF-NB-3rCDDP1000
Synonyms UKF-NB-3 CDDP
Accession CVCL_M478
Resource Identification Initiative To cite this cell line use: UKF-NB-3rCDDP1000 (RRID:CVCL_M478)
Comments Part of: Resistant Cancer Cell Line (RCCL) collection.
Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
Disease Neuroblastoma (NCIt: C3270)
Neuroblastoma (ORDO: Orphanet_635)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_9904 (UKF-NB-3)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): PubMed=31581737

Penta D8,15
Penta E12

Run an STR similarity search on this cell line
Web pages https://www.wass-michaelislab.org/rccl.php

Bedrnicek J., Vicha A., Jarosova M., Holzerova M., Cinatl J. Jr., Michaelis M., Cinatl J., Eckschlager T.
Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.
Neoplasma 52:415-419(2005)

PubMed=17505515; DOI=10.1038/sj.bjc.6603777
Blaheta R.A., Michaelis M., Natsheh I., Hasenberg C., Weich E., Relja B., Jonas D., Doerr H.-W., Cinatl J. Jr.
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.
Br. J. Cancer 96:1699-1706(2007)

PubMed=22170099; DOI=10.1038/cddis.2011.129
Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M., Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F., Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D., Cinatl J. Jr.
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Cell Death Dis. 2:e243.1-e243.8(2011)

PubMed=24466371; DOI=10.1593/tlo.13544
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013)

PubMed=27517323; DOI=10.18632/oncotarget.11160
Loschmann N., Michaelis M., Rothweiler F., Voges Y., Balonova B., Blight B.A., Cinatl J. Jr.
ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance.
Oncotarget 7:58051-58064(2016)

PubMed=27735941; DOI=10.1038/cddis.2016.257
Voges Y., Michaelis M., Rothweiler F., Schaller T., Schneider C., Politt K., Mernberger M., Nist A., Stiewe T., Wass M.N., Rodel F., Cinatl J. Jr.
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.
Cell Death Dis. 7:e2410.1-e2410.11(2016)

PubMed=31581737; DOI=10.3390/cells8101194
Povey J.F., Saintas E., Aderemi A.V., Rothweiler F., Zehner R., Dirks W.G., Cinatl J. Jr., Racher A.J., Wass M.N., Smales C.M., Michaelis M.
Intact-cell MALDI-ToF mass spectrometry for the authentication of drug-adapted cancer cell lines.
Cells 8:1194.1-1194.12(2019)

Encyclopedic resources Wikidata; Q54990334
Entry history
Entry creation05-Nov-2013
Last entry update29-Jun-2023
Version number13